Vadastuximab disitamab vedotin antibody-drug compound representing a important advancement in the treatment of acute myeloid leukemia (AML). This groundbreaking therapy precisely targets CD33, a antigen frequently found on leukemic blasts . The process involves binding to CD33, causing both cellular cytotoxicity and enhanced immune-mediated killing

The introduction of amivantamab offers a significant advance for individuals battling cancers featuring c-MET aberration. This unique antibody, a precise blocker of dual MET kinase and also human epidermal growth factor receptor 2 (HER2), demonstrated early results in clinical trials, particularly in patients whose tumors harbor measurable c-MET ex